[go: up one dir, main page]

AU2001249546A1 - Methods for treating disease with antibodies to cxcr3 - Google Patents

Methods for treating disease with antibodies to cxcr3

Info

Publication number
AU2001249546A1
AU2001249546A1 AU2001249546A AU4954601A AU2001249546A1 AU 2001249546 A1 AU2001249546 A1 AU 2001249546A1 AU 2001249546 A AU2001249546 A AU 2001249546A AU 4954601 A AU4954601 A AU 4954601A AU 2001249546 A1 AU2001249546 A1 AU 2001249546A1
Authority
AU
Australia
Prior art keywords
cxcr3
antibodies
methods
treating disease
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249546A
Inventor
Subhashini Arimilli
Shrikant Deshpande
Walter Ferlin
Simonetta Mocci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU2001249546A1 publication Critical patent/AU2001249546A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001249546A 2000-03-27 2001-03-27 Methods for treating disease with antibodies to cxcr3 Abandoned AU2001249546A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53559800A 2000-03-27 2000-03-27
US09535598 2000-03-27
PCT/US2001/009912 WO2001072334A2 (en) 2000-03-27 2001-03-27 Methods for treating disease with antibodies to cxcr3

Publications (1)

Publication Number Publication Date
AU2001249546A1 true AU2001249546A1 (en) 2001-10-08

Family

ID=24134913

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249546A Abandoned AU2001249546A1 (en) 2000-03-27 2001-03-27 Methods for treating disease with antibodies to cxcr3

Country Status (2)

Country Link
AU (1) AU2001249546A1 (en)
WO (1) WO2001072334A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US7405275B2 (en) 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
EP2115006A2 (en) * 2007-02-01 2009-11-11 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against cxcr3
SI2804878T1 (en) 2012-01-20 2018-12-31 Genzyme Corporation Anti-cxcr3 antibodies
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4502408B2 (en) * 1996-09-10 2010-07-14 テオドーア−コッヒャー インスティトゥーテ CXCR3 chemokine receptor, antibody, nucleic acid and method of use
US6171590B1 (en) * 1998-09-30 2001-01-09 Corixa Corporation Chemokine receptor peptide for inducing an immune response

Also Published As

Publication number Publication date
WO2001072334A2 (en) 2001-10-04
WO2001072334A3 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
MXPA03001590A (en) ANTIBODIES TO HUMAN IL-1bgr;.
AU2003257850A8 (en) Antibody specific to central tau-protein
IL156030A0 (en) Humanized antibodies
EP2270052B8 (en) Antibodies to OPGL
AU1174702A (en) Humanized anti-lt-beta-r antibodies
PT1361893E (en) Modified anti-egfr antibodies with reduced immunogenicity
AU4835001A (en) Antibodies to human cd154
IL161705A0 (en) Human monoclonal antibodies to dendritic cells
AU2002222112A1 (en) Hybrid antibodies
PL367324A1 (en) Antibodies to vla-1
IL166244A0 (en) Super humanized antibodies
AU6618100A (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
AU2003234706A1 (en) Antibodies that specifically bind to tl5
GB2387599B (en) Methods for producing antibodies
AU5441000A (en) Human monoclonal antibody
AU2003240822A1 (en) Antibodies that specifically bind to neurokinin b
AU2002351374A1 (en) Antibodies to treat cancer
AU2003302822A1 (en) Antibodies to treat cancer
AU2001249546A1 (en) Methods for treating disease with antibodies to cxcr3
AU2001280436A1 (en) Process to increase protein stability
AU2001280368A1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
AU2003280713A1 (en) Process for producing antibody
AU2001281099A1 (en) Production of human monoclonal antibodies
AU2001295042A1 (en) Anti-stilbene antibodies
EP1180240A4 (en) Process for utilizing epitopes recognized by natural antibodies